Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Vitrification has become the gold standard for oocyte and embryo cryopreservation. Several commercial kits are available on the market, some are designed for specific developmental stages (e.g. oocytes, zygotes, cleavage-stage embryos or blastocysts) and others are suitable for several stages, therefore termed "universal". Oocytes, cleavage-stage embryos and blastocysts display different levels of resistance to cryopreservation, due to stage-specific properties. While the composition and the exposition protocol of stage specific media are optimized for specific developmental stages, "universal" media display a single composition, therefore exposition protocols should be adapted to each specific developmental stage to ensure optimal survival rates.
The main objective of this study is to determine whether the shift from "oocyte specific" vitrification and warming media to "universal" media has an impact oocyte survival, embryological and clinical outcomes.
A retrospective, monocentric study comparing the clinical and embryological outcomes of 111 oocyte recipient cycles with ICSI from March 2016 to July 2020. Baseline characteristics (donor age and BMI, ovarian stimulation protocol, number of collected oocytes) of the 81 related donations were also analysed.
Two generations of vitrification and warming media were used during this period:
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| S/S - Vitrified and warmed with Oocyte-specific medium | 41 oocyte recipient ICSI cycles for which the initial oocyte vitrification procedure was performed with "oocyte- specific" medium RapidVit™ Oocyte (Vitrolife) and the warming procedure was performed with "oocyte-specific" medium RapidWarm™ Oocyte (Vitrolife) |
| |
| S/U - Vitrified with Oocyte-specific medium, Warmed with universal medium | 39 oocyte recipient ICSI cycles for which the initial oocyte vitrification procedure was performed with "oocyte- specific" medium RapidVit™ Oocyte (Vitrolife) and the warming procedure was performed with "universal" medium RapidWarm™ Omni (Vitrolife) |
| |
| U/U - Vitrified and warmed with universal medium | 31 oocyte recipient ICSI cycles for which the initial oocyte vitrification procedure was performed with "universal" medium RapidVit™ Oocyte (Vitrolife) and the warming procedure was performed with "universal" medium RapidWarm™ Omni (Vitrolife) |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Vitrification and warming media for oocyte vitrification | Other | Different combinations of the vitrification and warming media were used for oocyte vitrification procedure in the context of oocyte donation |
| Measure | Description | Time Frame |
|---|---|---|
| Impact of vitrification and warming media on clinical pregnancy rate per fresh embryo transfer | number of clinical pregnancies (one or more gestational sacs visualized in ultrasonography) expressed per 100 embryo transfers | UltraSound at 1 month after embryo transfer |
| Measure | Description | Time Frame |
|---|---|---|
| Impact of vitrification and warming media on oocyte survival rate | the number of injected oocytes divided by the number of warmed oocytes, expressed as a percentage (%) | two hours after warming procedure |
| Impact of vitrification and warming media on fertilization rate |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Oocyte recipient couples undergoing an oocyte donation ICSI
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Florence Brugnon | University Hospital, Clermont-Ferrand | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| CHU Clermont-Ferrand | Clermont-Ferrand | Auvergne | 63003 | France |
Not provided
| ID | Term |
|---|---|
| D007246 | Infertility |
| D007247 | Infertility, Female |
| ID | Term |
|---|---|
| D000091662 | Genital Diseases |
| D000091642 | Urogenital Diseases |
| D005831 | Genital Diseases, Female |
| D052776 | Female Urogenital Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D058989 | Vitrification |
| ID | Term |
|---|---|
| D044367 | Phase Transition |
| D055585 | Physical Phenomena |
Not provided
Not provided
Not provided
Not provided
Not provided
number of 2PN zygotes divided by the number of injected oocytes, expressed as a percentage (%) |
| 16-18 hours |
| Impact of vitrification and warming media on day-2 embryo percentage | number of cleavage-stage embryos obtained divided by the number of 2PN zygotes, expressed as a percentage (%) | 43-45 hours |
| Impact of vitrification and warming media on top-quality embryo percentage | Number of top-quality cleavage-stage embryos obtained divided by the total number of cleavage stage embryos, expressed as a percentage (%). | 43-45 hours |
| Impact of vitrification and warming media on blastulation rate | number of blastocysts obtained divided by the number of embryos subjected to extended culture, expressed as a percentage (%) | 114-118 hours |
| Impact of vitrification and warming media on good quality blastocyst rate | number of good quality blastocysts (ICM and trophoectoderm grade A or B obtained divided by the total number of blastocysts obtained, expressed as a percentage (%) | 114-118 hours |
| Impact of vitrification and warming media on implantation rate | number of gestational sacs with a cardiac activity visualized in ultrasonography divided by the number of embryo transferred, expressed as a percentage (%) | 114-118 hours |
| Impact of vitrification and warming media on live birth rate per embryo transfer | number live births expressed per 100 embryo transfers | 42 weeks |
| Impact of vitrification and warming media on miscarriage rate per embryo transfer | number miscarriages expressed per 100 embryo transfers | up to 42 weeks |
| D005261 | Female Urogenital Diseases and Pregnancy Complications |